Resiniferatoxin

Drug Profile

Resiniferatoxin

Alternative Names: MCP-101; RTX

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer ICOS Corporation; Mt Cook Pharma; National Institutes of Health (USA); Sorrento Therapeutics
  • Class Analgesics
  • Mechanism of Action TRPV cation channel agonists; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer pain
  • Discontinued Interstitial cystitis; Overactive bladder; Rhinitis

Most Recent Events

  • 29 Nov 2017 Sorrento and National Institutes of Health (USA) re-initiates enrolment in a phase I/II trial for Cancer pain in USA (Intrathecal) (NCT00804154)
  • 01 Aug 2017 Phase-I clinical trials in Cancer pain in USA (Epidural) (NCT03226574)
  • 30 Jun 2017 Sorrento Therapeutics plans a phase II trial for Cancer pain in late 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top